DUPImpact study demonstrates reduced exacerbations and improved asthma control in severe asthma patients, suggesting strong treatment benefits.
The DUPImpact study confirms the real-world effectiveness of dupilumab in reducing exacerbations and OCS use and improving asthma control and lung function. FEOS and EXACTO enable a multidimensional assessment beyond individual measures.
No takes yet. Share an insight, caveat, or question.
Izaguirre-Flores et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: